StockData
Provectus Biopharmaceuticals, Inc. logo

Provectus Biopharmaceuticals, Inc. (PVCT) shareholders

PVCTOTCPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 4/30
$0.05+0.00 (+0.39%)

Close on Oct 19, 2026Market cap $20.55MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
0.0%
0M of 420M shares
Institutional holders
4
0 new, 2 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Jeffrey Allen Morris61,100,61011.30%13G (passive)Aug 12, 2024
Pershing Edward52,441,27511.61%13D (active) amendmentJun 30, 2026
Dominic Rodrigues25,220,5495.67%13D (active)Dec 2, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of PVCTValueChange% of portfolio
Home Federal Bank Of Tennessee100,0000.02%$6.90K–0.00%
Atlas Wealth LLC19,6200.00%$1.36K–0.00%
Financial Symmetry Inc10,1910.00%$707–0.00%
Huntington National Bank10.00%$0–0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202640M0.0%0 / 00 / 20M0M
Q1 202660M0.0%1 / 00 / 00M0M
Q4 202550M0.0%0 / 00 / 20M0M
Q3 202570M0.1%0 / 10 / 00M0M
Q2 202570M0.1%0 / 00 / 00M0M
Q1 202570M0.1%1 / 00 / 00M0M
Q4 202460M0.0%0 / 00 / 10M0M
Q3 202470M0.1%0 / 02 / 00M0M
Q2 202470M0.1%1 / 10 / 00M0M
Q1 202460M0.0%0 / 00 / 00M0M
Q4 202370M0.1%1 / 00 / 00M0M
Q3 202360M0.1%0 / 00 / 10M0M

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Edward PershingCEO, Director, 10% owner3,532,9800.84%Nov 16, 2026
Dominic RodriguesPRESIDENT, Director1,201,2140.29%Jun 30, 2026
Eric Wachter PhdCTO6,649,2981.58%Dec 4, 2024
Heather RainesCFO1,213,1530.29%Dec 4, 2024
John Lacey IIIDirector200,4500.05%Jun 30, 2026
Webster BaileyDirector145,5280.03%Jun 30, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Jeffrey Allen Morris
10% owner
Aug 12, 2024Conversion+264,314$2.86$755.94K4,260,061
Jeffrey Allen Morris
10% owner
May 8, 2023Conversion+188,757$2.86$539.85K3,995,747
Heather Raines
CFO
Nov 10, 2020Award+50,000––1,213,153
Bruce Horowitz
Chief Operating Officer, Director
Nov 10, 2020Award+800,000––2,227,243
John Lacey III
Director
Nov 10, 2020Award+100,000––200,000
Heather Raines
Chief Financial Officer
Mar 25, 2019Award+50,000––1,163,153
John R. Glass
See Remarks
Dec 14, 2017Buy+115,900$0.05$5.80K200,000
John R. Glass
See Remarks
Dec 14, 2017Buy+84,100$0.05$4.21K84,100
Peter R. Culpepper
Interim CEO, CFO, COO
Mar 29, 2016Exercise+133,333$1.00$133.33K1,384,496
Peter R. Culpepper
Interim CEO, CFO, COO
Mar 29, 2016Exercise+27,333$1.00$27.33K1,411,829
Peter R. Culpepper
Interim CEO, CFO, COO
Mar 29, 2016Exercise+106,000$1.00$106.00K296,503
Eric Wachter Phd
Chief Technology Officer, Director
Mar 29, 2016Exercise+106,000$1.00$106.00K930,248
Eric Wachter Phd
Chief Technology Officer, Director
Mar 29, 2016Exercise+200,947$1.00$200.95K5,714,183
Jan Koe
Director
Mar 29, 2016Exercise+100,000$1.25$125.00K786,300
Jan Koe
Director
Mar 29, 2016Exercise+100,000$1.25$125.00K686,300
Eric Wachter Phd
Chief Technology Officer
Dec 21, 2015Option exercise+120,000$1.02$122.40K5,513,236
Peter R. Culpepper
CFO & COO
Dec 9, 2015Option exercise+138,831$0.94$130.50K1,251,163
Peter R. Culpepper
CFO & COO
Dec 9, 2015Option exercise+6,383$0.94$6.00K190,503
Eric Wachter Phd
Chief Technology Officer
Jan 24, 2015Option exercise+185,000$1.02$188.70K824,248
Timothy Scott Phd
President, Director
Jan 7, 2015Option exercise+76,764$0.64$49.13K503,125
Peter R. Culpepper
CFO & COO
Jan 7, 2015Option exercise+33,334$0.75$25.00K154,334
Peter R. Culpepper
CFO & COO
Jan 7, 2015Option exercise+29,786$0.94$28.00K184,120
Timothy Scott Phd
President, Director
Dec 30, 2014Option exercise+126,361$0.64$80.87K426,361
Timothy Scott Phd
President, Director
Oct 29, 2014Option exercise+96,875$0.64$62.00K1,521,845
Peter R. Culpepper
CFO & COO
Jun 28, 2014Option exercise+100,000$1.25$125.00K1,112,332
Timothy Scott Phd
President
May 19, 2014Option exercise+25,000$0.95$23.75K1,424,970
Timothy Scott Phd
President
May 19, 2014Option exercise−25,000$0.95$23.75K1,424,970
Eric Wachter Phd
Chief Technology Officer
Mar 20, 2014Option exercise+25,000$0.95$23.75K5,418,236
Eric Wachter Phd
Chief Technology Officer
Mar 20, 2014Option exercise+600,000$0.93$558.00K6,032,484
Eric Wachter Phd
Chief Technology Officer
Mar 20, 2014Option exercise+14,248$0.75$10.69K5,432,484
Timothy Scott Phd
President
Feb 26, 2014Option exercise+300,000$1.10$330.00K300,000
Peter R. Culpepper
CFO & COO
Feb 26, 2014Option exercise+68,624$1.10$75.49K1,012,332
Peter R. Culpepper
CFO & COO
Feb 26, 2014Option exercise+121,000$1.10$133.10K121,000
Jan Koe
Director
Sep 20, 2013Buy+100,000––586,300
H. Craig Dees
Chief Executive Officer, Director
May 29, 2013Option exercise+18,750$0.32$6.00K1,472,859
H. Craig Dees
Chief Executive Officer, Director
May 29, 2013Option exercise+25,000$0.60$15.00K1,497,859
Peter R. Culpepper
CFO, COO
Dec 3, 2012Buy+133,333––943,708
Peter R. Culpepper
CFO, COO
Nov 16, 2012Buy+133,333––810,375
Eric Wachter Phd
Chief Technology Officer
Nov 16, 2012Buy+666,666––5,393,236
Eric Wachter Phd
Vice President Pharmaceuticals, Director
Dec 5, 2011Option exercise+100,000$0.75$75.00K4,726,570
Eric Wachter Phd
Vice President Pharmaceuticals, Director
Dec 1, 2011Option exercise+100,000$0.93$93.00K4,626,570
Eric Wachter Phd
Vice President Pharmaceuticals, Director
Nov 23, 2011Option exercise+100,000$0.93$93.00K4,526,570
Eric Wachter Phd
Vice President Pharmaceuticals, Director
Oct 19, 2011Option exercise+100,000$0.93$93.00K4,426,570
Timothy Scott Phd
President, Director
Oct 6, 2011Option exercise+25,000$0.60$15.00K1,399,970
Timothy Scott Phd
President, Director
Oct 6, 2011Option exercise+75,000$0.32$24.00K1,374,970
Eric Wachter Phd
Vice President Pharmaceuticals, Director
Sep 7, 2011Option exercise+100,000$0.93$93.00K4,326,570
Eric Wachter Phd
Vice President Pharmaceuticals, Director
Jul 29, 2011Option exercise+100,000$1.00$100.00K4,226,570
Eric Wachter Phd
Vice President Pharmaceuticals, Director
May 3, 2011Option exercise+100,000$1.00$100.00K4,126,570
Peter R. Culpepper
Chief Financial Officer
May 3, 2011Option exercise+133,333$0.75$100.00K677,042
Eric Wachter Phd
Vice President Pharmaceuticals, Director
Apr 20, 2011Option exercise+100,000$1.00$100.00K4,026,570
Eric Wachter Phd
Vice President Pharmaceuticals, Director
Apr 12, 2011Option exercise+150,000$1.00$150.00K3,926,570
Eric Wachter Phd
Vice President Pharmaceuticals, Director
Feb 7, 2011Option exercise+8,333$0.75$6.25K3,776,570
Eric Wachter Phd
Vice President Pharmaceuticals, Director
Feb 3, 2011Option exercise+125,000$0.75$93.75K3,768,237
Eric Wachter Phd
Vice President Pharmaceuticals, Director
Dec 29, 2010Option exercise+400,000$1.00$400.00K3,643,237
Peter R. Culpepper
Chief Financial Officer
Dec 29, 2010Option exercise+133,333$0.75$100.00K543,709
Eric Wachter Phd
Vice President Pharmaceuticals, Director
Nov 19, 2010Option exercise+100,000$1.00$100.00K3,243,237
Eric Wachter Phd
Vice President Pharmaceuticals, Director
Sep 7, 2010Option exercise+100,000$1.00$100.00K3,143,237
Eric Wachter Phd
Vice President Pharmaceuticals, Director
Jul 9, 2010Option exercise+75,000$1.10$82.50K3,043,237
Eric Wachter Phd
Vice President Pharmaceuticals, Director
Apr 28, 2010Option exercise+52,419$0.75$39.31K2,968,237
Eric Wachter Phd
Vice President Pharmaceuticals, Director
Apr 28, 2010Option exercise+105,469$0.64$67.50K2,915,818

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
–
1M shares short
Days to cover
4.6
At 0M shares a day
Change since last report
0.0%
From 1M shares
Short volume, 0 days
–
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Provectus Biopharmaceuticals's stock actually held short. No settlement fails above the SEC's reporting threshold in the last 90 days.

See a number that looks wrong?